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Introduction: Health-related quality of life (HQL) parameters have never been tested in patients having chon-
dromas/chondrosarcomas who are being treated with protons. The aim of this study was to document changes
in HQL of chordoma/chondrosarcoma patients treated with proton beam radiotherapy. Treatments commenced
in September 2011 at CNAO, and HQL studies were initiated in January 2012 for all patients undergoing treat-
ment. Methods: The validated Italian translation of the EORTC QLQ-C30 version 3.0 was used for HQL evalu-
ation. The HQL assessments were made prior to starting radiation and at completion of treatment. Scoring was
as per the EORTC manual. As per standard norms, a difference of >10 points in the mean scores was taken to be
clinically meaningful. Results: Between January and September 2012, 17 patients diagnosed with chordoma or
chondrosarcoma, with a mean ± SD age of 49.5 ± 16.4 years, had completed treatment. The involved sites were
skull base (n = 12) and sacral/paraspinal (n = 5). The prescribed dose was 70–74 GyE at 2 GyE per fraction,
5 days/week. When comparing pre- and post-treatment scores, neither a clinically meaningful nor a statistically
significant change was documented. Conclusions: During treatment, HQL is not adversely affected by protons,
allowing normal life despite the long course of treatment. This is an ongoing study and more long-term assess-
ment will help evaluate the actual impact of proton therapy on HQL for these slow-responding tumours.
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INTRODUCTION
In recent years, success or failure of a therapy for a specific
disease was assessed in terms of overall survival, local
control or complication rate. These objective parameters,
assessed by the physician, formed the gold standard for
evaluating and comparing outcomes. Though these did give
an indication regarding the success or failure of the treat-
ment methodology per se, they did not provide any infor-
mation regarding the patient’s mental and emotional
wellbeing or the impact of the disease on the patient [1].
The treatment would be considered to be successful if the
disease was controlled and survival prolonged, without con-
sidering the detrimental effects of the disease and the treat-
ment on the daily life of the patient. Health-related quality
of life (HQL) refers to the patient’s perception of the
effects of the disease and the impact on the patient’s daily
functioning. The survey (EORTC-QLQ C30ver 3.0) used in
this study is multidimensional, incorporating all aspects of
daily life, and it is subjective, i.e. self-reported by the
patient [2, 3]. Recently, there has been a surge of interest in
these aspects and more emphasis is being placed upon
preserving a good quality of life (QOL) while improving/
maintaining the objective measures of outcome, like
disease control and survival.
Chordomas and chondrosarcomas are rare tumours that are
usually slow growing with a tendency to be diagnosed at a
relatively advanced stage, which usually present for radiother-
apy after several resections have been attempted [4, 5]. They
have a predilection to involve the appendicular skeleton and
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develop in close proximity to important anatomical structures
like the optic apparatus, cranial nerves, brainstem, spinal
cord and cauda equina, making surgical resection difficult.
Complete surgical resection of these tumours offers the best
control rates but is rarely achievable, and even after complete
resections, there is a risk of microscopic residual disease that
is at a high risk for recurrence [6]. Maximal surgical resection
followed by radiotherapy has been found to have the best
control rates, even though radiation alone itself has not been
found to be very effective [7]. These are designated as relative-
ly radioresistant tumours, and optimal doses of radiation are
needed to effect local control [8, 9]. However, delivery of
optimal doses with conventional techniques is difficult, and
dose to the tumour needs to be scaled in keeping with the
lower tolerance doses of the adjacent normal tissues.
Proton beam therapy is an emerging option that is
expected to be superior to conventional photon therapy, pri-
marily because of its ability to deposit optimal doses at the
tumour site while limiting exposure of the adjacent normal
tissues. This provides an opportunity to deliver higher doses
to the tumour while respecting the tolerance of the normal
tissues. Thus proton beam therapy can be expected to have
the greatest possible survival with the fewest and least severe
side effects [10, 11]. If this can be accomplished, then it is
assumed that the QOL of the patients would be improved.
However, it has to be emphasized that there also exists a pos-
sibility, though rare, that some types of side effects could be
made worse due to incorrect relative biological effectiveness
(RBE) allocation, Bragg peak positioning errors, or excess
skin (entry) dose compared to photons, adversely affecting
HQL. There is no published data on the quality-of-life
changes in patients with chordomas or chondrosarcomas
treated with proton beam therapy. This study aims to evaluate
whether the HQL of these patients is affected during treat-
ment with proton beam therapy. A prospective longitudinal
evaluation of QOL of patients histologically diagnosed as
having chordoma/chondrosarcoma of skull base or spine,
who were treated at the Italian National Hadrontherapy
Center for Cancer (CNAO) was performed, and the results of
the same are discussed here.
MATERIALS ANDMETHODS
Study population
Proton therapy treatments at the Italian National Hadrontherapy
Center (CNAO) at Pavia, Italy started in September 2011. A
quality-of-life study of chordoma and chondrosarcoma patients
was initiated in January 2012. Between January 2012 and July
2012, 17 patients had been treated within the approved proto-
cols for chordoma or chondrosarcoma.
All patients were treated with proton beam therapy at the
conventional fractionation of 2 GyE per fraction for 5 days a
week to a total dose of 70 GyE for chondrosarcoma and
74 GyE for chordoma. The average treatment duration was
52.5 ± 4 SD days with a range of 45–59 days. There were no
toxicity-related treatment breaks.
Additionally the attending physician scored the patient on
four parameters viz. mobility, self-care, pain/discomfort and
anxiety/depression on a scale of 1–3, with 1 indicating no
problems/limitations and 3 indicating severe limitation.
EORTC QLQ C-30 questionnaire
The EORTC QLQ C-30 questionnaire has 30 questions that
cover 15 HQL parameters that can be grouped as five func-
tional scales (physical, role, cognitive, emotional and social
functioning), three symptom scales (fatigue, pain and
nausea/vomiting), six single-item scales (dyspnoea, appetite
loss, constipation, diarrhoea, financial difficulties and insom-
nia) and global health status. All the items were scored on
a four-point scale ranging from 1–4 with 1 = not at all,
2 = a little, 3 = quite a bit, and 4 = very much. These scores
are then transformed to a continuous scale from 0–100, with
a higher score of the functional and global health status des-
ignating a better QOL and a higher score of the symptom
scales meaning a higher symptomatology.
A clinically important difference was designated when
there was a 10-point difference between the scores at differ-
ent time-points [12].
For this study a validated Italian translation of the ques-
tionnaire was used after seeking permission from EORTC.
The questionnaires were handed out to the patients as
paper handouts before start of therapy and at the end of treat-
ment by the nurse, and were collected the following day.
The patients were required to complete the questionnaires
themselves.
Statistical analysis
Continuous variables were expressed as mean ± SD (range).
Scoring was performed as per the instructions in the EORTC
scoring manual. The statistical software program SPSS
version 14 (SPSS Inc., Chicago) was used for data analysis.
The difference between pre- and end-of-treatment scores was
assessed by using the Mann Whitney test.
RESULTS
Characteristics of the patients included in this study are
depicted in Table 1.
Physician-scored pre-treatment status
When assessed prior to start of treatment most of the patients
were categorized into the ‘no problem’ group for all para-
meters viz. mobility, self-care, pain/discomfort and anxiety/
depression. Only 6–29% of patients were assessed to have
some problem, while 12% were scored as having severe lim-
itations (Table 2).
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Global health status
The mean ± SD pre- and post-treatment scores were 71 ±
24.5 and 68.1 ± 18.6, respectively. The mean scores were
neither statistically significant nor clinically important
(Table 3).
Functional scores
The mean ± SD pre-treatment scores for physical, role, emo-
tional, cognitive and social functioning were 80.3 ± 30.5,
82.3 ± 29.7, 77.4 ± 32.1, 84.3 ± 31.4, 78.4 ± 34.7, while the
post-treatment scores were 81.2 ± 28.8, 77.4 ± 32.2, 85.7 ±
24.8, 88.2 ± 21.9, 79.4 ± 30.4, respectively (Table 3). These
differences were neither statistically significant nor found to
be clinically important.
When data was assessed with stratification in the form of
no change (no change between pre- and post-treatment
scores), trivial change (<4 points change), small difference
(4–10 points change), and clinically important difference
(>10 points change) for each category individually, clinically
important differences were detected in all domains of QOL
(Table 4).
Symptom scores
Given the location of the tumour, the symptoms were primar-
ily skeletal and neurological. Subsequently, fatigue, pain, in-
somnia and financial difficulty were chosen for reporting
here, as the remaining symptoms like nausea/vomiting, dys-
pnoea, constipation, diarrhoea and loss of appetite were not
encountered in this particular group of patients. The mean ±
SD pre-treatment scores for fatigue, pain, insomnia and finan-
cial difficulty were 28.7 ± 30.4, 10.7 ± 18.5, 27.4 ± 35.8 and
23.5 ± 28.3, while post-treatment scores were 32.8 ± 30.9,
11.7 ± 16.4, 19.6 ± 26.5 and 33.33 ± 33.33. None of the
changes in these parameters were statistically significant,
however when individual patient data was analysed, a clinically
important improvement in fatigue, pain, sleep and financial dif-
ficulty was documented in 18%, 12%, 35% and 12% of the
patients, respectively, while clinically important deterioration
for the same was documented in 35%, 24%, 24% and 24% of
cases, respectively (Tables 3 and 4). The statistical significance
of this could not be assessed due to the very low number of
events.
Toxicities
The maximal acute site-specific toxicities recorded in the
patients are as shown in Tables 5 and 6. As seen by the data
in the tables, the total number of events reported was few and
the highest toxicity recorded was Grade II.
DISCUSSION
To best of our knowledge this is the first study to assess
quality-of-life parameters in patients with chordomas/
chondrosarcomas treated with protons. Additionally, no com-
parable data on QOL in these patients has been reported from
the photon therapy world. We found that QOL parameters
are maintained during treatment.
Given the location and natural history of these tumours,
multiple surgeries are often needed for maximal surgical re-
section, and the potential toxicity associated with repeated
excisions in areas like the base of skull can lead to consider-
able morbidity with a rate of 23–33% for new neurological
injuries and 9–10% for cerebrospinal fluid leakage [13, 14].
Radical resection is difficult to achieve, consequently
debulking or partial resections are usually performed. The
standard for primary treatment is therefore a combination of
surgery and radiotherapy [15] to improve the local control
rate. In our set of patients surgery was performed in all
except one case of sacral chordoma that was assessed to be
unresectable, in which case only a biopsy was taken.
These tumours are classically considered radioresistant [16–
18], and the use of radiation has been debated. However, with
improved techniques of delivering radiation, higher doses can
Table 2. Physician-assessed pre-treatment scores
Parameter No problem
Some
problem
Severe
limitation
Mobility 82% (14) 6% (1) 12% (2)
Self-care 82% (14) 6% (1) 12% (2)
Pain/discomfort 70% (12) 18% (3) 12% (2)
Anxiety/depression 59% (10) 29% (5) 12% (2)
Table 1. Patient characteristics
Gender 8 males; 9 females
Age 49.5 ± 16.4
years(21–73)
Histology Chordoma 77% (13)
Chondrosarcoma 23% (4)
Location/Site Skull Base 70.5% (12)
Sacrum/paraspinal 29.4% (5)
Prior surgery Mean 1; Min–Max (0–4)
Prior radiotherapy None
Occupation Employed 59% (10)
Unemployed 12% (2)
Retired 29% (3)
Marital status Living with partner 59% (10)
Living alone 41% (7)
Children Yes 53% (9)
No 47% (8)
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be delivered and local control rates can be improved. Protons
have an advantage in such scenarios on account of their dose
deposition characteristics, and can deposit high doses to the
target while respecting the tolerance doses of the surrounding
normal organs [19]. It is expected that sparing of the normal
tissues can decrease the incidence and severity of the toxicities,
thereby helping maintain a good QOL.
Use of QOL measurement in the clinical oncological
setting has been shown to improve patient–clinician com-
munication and to be associated with improved QOL and
emotional functioning of the patients [20]. The QOL ques-
tionnaire can be used as a communication aid with which
patients can describe their side effects to clinicians, and it
has been demonstrated by Detmar et al. [2] as facilitating
patient–clinician communication and improving clinician
awareness of patient QOL issues. It provides the patients’
perspective, and it has been shown to differ from physician-
evaluated assessments [21]. This fact was clearly depicted in
the discordance seen between the assessments of physical ac-
tivity status by the patients and by the physicians. As per the
observation of the physician in charge, 82% of the patients
had no problems with mobility and could take care of them-
selves without effort, and the evaluation continued to be the
same during the course of treatment. From the patients’ point
of view, 29% of the patients self-assessed their physical
functioning as not having changed during the course of treat-
ment, while 18% reported improvement and 12% reported
deterioration in the physical functioning score that was
deemed to be clinically significant, even though not statistic-
ally significant. Similarly, for emotional functioning, 47% of
Table 3. Pre-treatment versus end-of-treatment mean scores
Pre-treatment End-of-treatment P-value
Clinically important
difference
Global health status 71 ± 24.5 68.1 ± 18.6 0.5 No
Physical functioning 80.3 ± 30.5 81.2 ± 28.8 0.9 No
Role functioning 82.3 ± 29.7 77.4 ± 32.2 0.1 No
Emotional functioning 77.4 ± 32.1 85.7 ± 24.8 0.09 No
Cognitive functioning 84.3 ± 31.4 88.2 ± 21.9 0.2 No
Social functioning 78.4 ± 34.7 79.4 ± 30.4 0.7 No
Fatigue 28.7 ± 30.4 32.8 ± 30.9 0.4 No
Pain 10.7 ± 18.5 11.7 ± 16.4 0.9 No
Sleep 27.4 ± 35.8 19.6 ± 26.5 0.2 No
Financial difficulty 23.5 ± 28.3 33.33 ± 33.33 0.2 Yes
Table 4. Changes in quality-of-life domains
No change Trivial (<4) Small (4–10)
Medium/Clinically
important difference
(>10)
Improve Deteriorate Improve Deteriorate Improve Deteriorate
Global 6% (1) 0 0 12% (2) 24% (4) 24% (4) 35% (6)
Physical 29% (5) 0 0 18% (3) 24% (4) 18% (3) 12% (2)
Role 71% (12) 0 0 0 0 6% (1) 24% (4)
Emotional 47% (8) 0 0 18% (3) 6% (1) 24% (4) 6% (1)
Cognitive 77% (13) 0 0 0 0 17% (3) 6% (1)
Social 59% (10) 0 0 0 0 17% (3) 23% (4)
Fatigue 41% (7) 0 6% (1) 0 0 18% (3) 35% (6)
Pain 65% (11) 0 0 0 0 12% (2) 24% (4)
Sleep 41% (7) 0 0 0 0 35% (6) 24% (4)
Financial difficulty 65% (11) 0 0 0 0 12% (2) 24% (4)
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the patients reported no change in status during the course of
treatment, 24% reported improvement and 6% reported de-
terioration. This phenomenon can be attributed to the psy-
chological impact of undergoing treatment itself, especially
in cases that had been previously stated to be unresectable or
which had large residuals after surgery and no other option
available for further treatment. When proton beam therapy
was offered as a treatment in such difficult scenarios,
patient’s anxiety and uncertainty regarding the disease
process was decreased, which may have been reflected in
improved emotional functioning scores.
Fatigue is a common problem encountered in patients of
cancer who undergo radiotherapy [22, 23]. It has been docu-
mented as one of the three most negative items affecting
QOL in cancer patients. In this subset of patients, no change
in fatigue scores was recorded by 41%, worsening was
reported in 35%, while improvement was noted in 18% of
the patients when comparing the end-of-treatment scores
with the pre-treatment scores. As seen in the PARSPORT
trial, intensity-modulated radiotherapy (IMRT) is associated
with increased fatigue scores compared with conventional
irradiation, and this can result in deterioration of the general
wellbeing of the patients undergoing IMRT [24]. Despite
changes in fatigue scores reported in this study group, no sig-
nificant impact on the HQL was found. These are slow-
responding tumours and are not known to change during the
course of treatment. Consequently, symptoms associated with
the disease resolve gradually. In keeping with this, pain scores
did not change in 65%, deteriorated in 24%, and improved in
12% of the cases. Difficulty in sleeping was improved in 35%,
worsened in 24%, and not changed in 41% of patients towards
the end of treatment. The improvement could be attributed to
decreased anxiety or decreased pain/symptoms.
The other major problem that was cited by the patients
was ‘financial difficulty’, even though the patient was not
paying for the treatment, as they had been treated in the ex-
perimental phase of the machine according to the rules of the
Italian Health Ministry. The probable reason for this was the
costs incurred by the patient when living away from their
home during the duration of the treatment (carried out on an
out-patient basis).
Apart from global health status and physical functioning
scores, there was no change in the majority of cases with respect
to the remaining functional domains/symptom scores when
comparing pre- versus end-of-treatment values. When compar-
ing the clinically important differences, the results were very
heterogeneous, with some patients improving and others deteri-
orating. It is too early to draw a firm conclusion from this
scenario, given the short follow-up and the small sample. As
mentioned, these are slow-responding tumours and there is a
possibility that late effects may have an impact on the HQL later.
The treatments were well tolerated by all patients and the
maximum toxicities scored as per CTCAE version 3 were
Grade 2, as depicted in Tables 5 and 6. These have been dis-
cussed in detail by Tuan et al. [25] in this journal. The most
common toxicity reported was dermatitis, which is in keeping
with the fact that protons lack the skin-sparing effect associated
with photons. There were no interruptions in treatment due to
toxicities.
Patient-reported outcomes like QOL are subjective and can
be affected by a number of factors, both treatment and non-
treatment related. Though it was not possible to carry out a
statistical correlation of QOL with acute toxicity scores due to
the small sample size, the low incidence and severity of acute
side events reported with the proton treatment suggests that
such treatments are very well tolerated. It can be safely pre-
sumed that QOL is maintained during treatment despite the
lack of statistically significant data and the small sample size.
CONCLUSION
Assessment of QOL forms an integral part of patient-
reported outcome measures. This type of study in chordoma/
chondrosarcoma patients treated with proton beam therapy is
Table 5. Skull base treatment: maximal toxicity recorded
and number of patients [25]
Grade
1
Grade
II
Grade
III
Grade
IV
Vomiting 1 1 0 0
Nausea 2 1 0 0
Fatigue 0 0 0 0
Headache 5 0 0 0
Hypersomnia 0 0 0 0
Dermatitis 11 1 0 0
Superficial soft tissue
fibrosis
0 0 0 0
Oral mucositis 2 1 0 0
Dysphagia 0 0 0 0
Table 6. Sacral and spinal treatments: maximal toxicity
recorded and number of patients [25]
Grade
I
Grade
II
Grade
III
Grade
IV
Dermatitis 4 2 0 0
Superficial soft tissue
fibrosis
0 0 0 0
Proctitis 0 0 0 0
Cystitis 0 0 0 0
Rectal pain 0 0 0 0
Nausea 0 0 0 0
Diarrhoea 0 0 0 0
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unique. We were unable to find any such similar study in the
literature, thus ruling out the possibility of comparison with
similar studies.
It is too early to draw firm conclusions regarding the
changes in HQL with proton therapy treatment. As these are
slow-responding tumours, longer follow-ups may reveal add-
itional information regarding HQL changes. Consequently it
will be essential to re-evaluate QOL in these patients at
repeated intervals. This is an ongoing study at CNAO and
results will be updated at a later date. However, it can be
safely concluded that QOL scores were at the very least
maintained, if not improved, in the majority of the patients
during the course of proton beam therapy.
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